BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today confirmed that its partner, R-Tech Ueno, Ltd. (“RTU”) (Osaka Securities Exchange Hercules code: 4573), reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings. Furthermore, although there was an irritation upon instillation, there were no severe adverse effects.
